magnesium carbonate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4288	546-93-0

Description:

Molecule	Description
Synonyms: magnesium carbonate carbonic acid magnesium salt	Molecular weight: 84.31 Formula: CMgO3 CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

magnesium carbonate
carbonic acid magnesium salt

Molecular weight: 84.31
Formula: CMgO3
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
7	g	O

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Oct. 2, 1990	FDA	UNITED GUARDIAN

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Vaginal flatulence	62.79	14.43	19	5006	3274	63480723
Proctitis	57.23	14.43	20	5005	5421	63478576
Radiculopathy	48.30	14.43	20	5005	8591	63475406
Female genital tract fistula	47.34	14.43	19	5006	7540	63476457
Vaginal discharge	43.74	14.43	19	5006	9179	63474818
Chronic sinusitis	37.68	14.43	19	5006	12824	63471173
Colitis	35.57	14.43	30	4995	48498	63435499
Paraesthesia oral	33.05	14.43	20	5005	19236	63464761
Frequent bowel movements	32.19	14.43	21	5004	23001	63460996
Macular degeneration	31.10	14.43	21	5004	24355	63459642

Showing 1 to 10 of 30 entries

Previous1 2 3Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Blood phosphorus increased	72.15	20.48	27	3176	7694	34946034
Appendicolith	69.31	20.48	27	3176	8574	34945154
Appendicitis	61.28	20.48	29	3174	14778	34938950
Myasthenia gravis	49.66	20.48	20	3183	6920	34946808
Cardiogenic shock	47.85	20.48	30	3173	26588	34927140
Ventricular fibrillation	46.69	20.48	28	3175	22926	34930802
Blood uric acid increased	46.52	20.48	21	3182	9603	34944125
Mesothelioma	45.08	20.48	10	3193	435	34953293
Dry mouth	44.42	20.48	30	3173	30135	34923593
Stress	39.55	20.48	28	3175	30319	34923409

Showing 1 to 10 of 26 entries

Previous1 2 3Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Appendicolith	71.88	14.95	27	6624	8524	79729213
Blood phosphorus increased	70.35	14.95	28	6623	10319	79727418
Vaginal flatulence	61.95	14.95	18	6633	2557	79735180
Appendicitis	57.31	14.95	30	6621	20764	79716973
Proctitis	49.34	14.95	19	6632	6413	79731324
Hyponatraemia	49.06	14.95	67	6584	177781	79559956
Female genital tract fistula	47.09	14.95	18	6633	5957	79731780
Blood uric acid increased	44.77	14.95	22	6629	13338	79724399
Myasthenia gravis	43.66	14.95	20	6631	10379	79727358
Radiculopathy	43.53	14.95	19	6632	8805	79728932

Showing 1 to 10 of 45 entries

Previous1 2 3 4 5Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	A02AA01	ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS ANTACIDS Magnesium compounds
ATC	A06AD01	ALIMENTARY TRACT AND METABOLISM DRUGS FOR CONSTIPATION DRUGS FOR CONSTIPATION Osmotically acting laxatives
CHEBI has role	CHEBI:33287	fertilizers
CHEBI has role	CHEBI:65265	antacids
MeSH PA	D057886	Bleaching Agents
MeSH PA	D058427	Hygroscopic Agents
MeSH PA	D016877	Oxidants

Showing 1 to 7 of 7 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Peptic ulcer	indication	13200003	DOID:750
Constipation	indication	14760008	DOID:2089
Heartburn	indication	16331000
Indigestion	indication	162031009
Hypomagnesemia	indication	190855004
Gastroesophageal reflux disease	indication	235595009	DOID:8534
Incomplete passage of stool	indication	249515001
Struvite Renal Calculi	indication
Calcium Phosphate Renal Calculi	indication
Hiatal Hernia with Reflux Esophagitis	indication

Showing 1 to 10 of 51 entries

Previous1 2 3 4 5 6Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

Show entries

Search:

ID	Source
000785	NDDF
001120	NDDF
007230	NDDF
0E53J927NA	UNII
11029	PUBCHEM_CID
17968-26-2	SECONDARY_CAS_RN
29155	RXNORM
29720	MMSL
387401007	SNOMEDCT_US
4017631	VUID

Showing 1 to 10 of 22 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
ACID GONE ANTACID	HUMAN OTC DRUG LABEL	2	0904-7727	LIQUID	358 mg	ORAL	OTC monograph final	10 sections
Acid Gone AntacidExtra Strength	HUMAN OTC DRUG LABEL	2	0904-5365	TABLET, CHEWABLE	105 mg	ORAL	OTC monograph final	12 sections
Acid Gone AntacidExtra Strength	HUMAN OTC DRUG LABEL	2	0904-5365	TABLET, CHEWABLE	105 mg	ORAL	OTC monograph final	12 sections
EXTRA STRENGTH HEARTBURN RELIEF ANTACID	HUMAN OTC DRUG LABEL	2	11822-6862	SUSPENSION	237.50 mg	ORAL	OTC monograph final	10 sections
Extra StrengthAntacid	HUMAN OTC DRUG LABEL	2	11673-814	TABLET, CHEWABLE	105 mg	ORAL	OTC monograph final	12 sections
Extra StrengthAntacid	HUMAN OTC DRUG LABEL	2	11673-814	TABLET, CHEWABLE	105 mg	ORAL	OTC monograph final	12 sections
FAST ACTING Heartburn Relief	HUMAN OTC DRUG LABEL	2	0363-1155	TABLET, CHEWABLE	105 mg	ORAL	OTC monograph final	12 sections
FAST ACTING Heartburn Relief	HUMAN OTC DRUG LABEL	2	0363-1155	TABLET, CHEWABLE	105 mg	ORAL	OTC monograph final	12 sections
GAVISCON	HUMAN OTC DRUG LABEL	2	0135-0094	LIQUID	358 mg	ORAL	OTC monograph final	13 sections
GAVISCON	HUMAN OTC DRUG LABEL	2	0135-0095	LIQUID	237.50 mg	ORAL	OTC monograph final	13 sections

Showing 1 to 10 of 30 entries

Previous1 2 3Next